Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy

Area of Science:

• Oncology
• Biochemistry
• Medical Chemistry

Background:

• Photodynamic therapy (PDT) efficacy is often limited by poor photosensitizer (PS) specificity for cancerous tissues.
• Current strategies to improve PS targeting primarily rely on protein-protein interactions, such as monoclonal antibodies against tumor antigens like HER2 or EGFR.
• Aberrant glycosylation, specifically the overexpression of truncated O-glycans like T/Tn antigens, presents a distinct hallmark of many tumors.

Purpose of the Study:

• To explore the potential of targeting tumor-specific glycosylation aberrations for improved photosensitizer delivery in photodynamic therapy.
• To investigate the conjugation of photosensitizers to molecules that recognize aberrant O-glycans on cancer cell surfaces.

Main Methods:

• Conjugation of photosensitizers (PS) to targeting molecules.
• Utilizing molecules that specifically recognize aberrant O-glycosylation patterns, such as T/Tn antigens.
• Evaluating the specificity and efficacy of these targeted PS in preclinical cancer models.

Main Results:

• Development of novel photosensitizer conjugates designed for targeted delivery.
• Demonstration of specific binding of PS conjugates to cancer cells overexpressing T/Tn antigens.
• Potential for enhanced photodynamic effect in tumor tissues due to improved PS accumulation.

Conclusions:

• Targeting tumor-specific O-glycosylation aberrations represents a promising alternative strategy to enhance photosensitizer specificity in photodynamic therapy.
• This approach could overcome limitations associated with traditional protein-targeting methods.
• Further research into O-glycan-targeted PDT holds potential for more effective cancer treatment.